Benzinga | Aug 6, 2020 04:27PM EDT

Clovis Oncology Q2 EPS $(1.15) Misses $(1.04) Estimate, Sales $39.90M Miss $44.65M Estimate

Clovis Oncology (NASDAQ:CLVS) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(1.04) by 10.58 percent. This is a 36.11 percent increase over losses of $(1.80) per share from the same period last year. The company reported quarterly sales of $39.90 million which missed the analyst consensus estimate of $44.65 million by 10.64 percent. This is a 20.99 percent increase over sales of $32.98 million the same period last year.